A
Acrivon Therapeutics
Biotech company specializing in drug development through early clinical treatment success
About Acrivon Therapeutics
Acrivon Therapeutics is a clinical-stage oncology company focused on developing targeted therapies to improve the lives of cancer patients. Operating at the frontier of proteomics, Acrivon employs its proprietary precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop a robust drug pipeline. The AP3 platform generates OncoSignature companion diagnostics, which are designed to accurately identify patients whose tumors are predicted to be sensitive to Acrivon's drug candidates. This approach aims to revolutionize precision oncology drug development and treatment by ensuring that therapies are matched with patients who are most likely to benefit, regardless of underlying genetic tumor alterations. Acrivon serves patients suffering from various types of cancer, aiming to provide more effective and personalized treatment options. The company operates within the precision oncology market, which focuses on tailoring medical treatment to the individual characteristics of each patient's disease. Acrivon's business model involves the development and commercialization of its proprietary therapies and companion diagnostics, generating revenue through the sale of these products and potentially through partnerships and collaborations with other pharmaceutical companies.
Source: Dealroom company dataNews
Open roles
Acrivon Therapeutics in the Cambridge ecosystem
The Acrivon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
Citadel
Wellington Management
RA Capital Management
Perceptive Advisors
Marshall Wace- HPHealthCor Partners
HBM Healthcare Investments
Sands Capital Management
Alexandria Venture Investments
Alexandria Equities
Pureos Bioventures
Acorn Bioventures
Surveyor Capital
Chione Ltd
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Acrivon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Acrivon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

